Clinical Trial Update: Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating acalabrutinib in combination with the R-ICE chemotherapy regimen for relapsed or refractory lymphoma; the study was terminated with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Acalabrutinib (Calquence) (acalabrutinib)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: University of Miami | Conditions: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2022-09-19